Posted: Tuesday, December 13, 2016
BodyCap, a company specialized in miniaturized wireless monitoring devices, today announces that two of its wearable health monitoring devices are currently being used by European Space Agency (ESA) astronaut Thomas Pesquet aboard the International Space Station (ISS), as part of ESA’s EveryWear program, an ambulatory data collection system.
This program, developed by France’s space agency CNES (Centre National d’Etudes Spatiales), its affiliate CADMOS, a ground laboratory focusing on microgravity science, and space medicine specialists MEDES (Institute for Space Medicine and Physiology) includes a personal assistant that astronauts use via a tablet named EveryWear. ESA astronaut Thomas Pesquet will be the first to use it, during his six-month Proxima mission.
EveryWear combines input from three wearable sensors, two of which are provided by BodyCap:
e-TACT will be commercially available in Europe and the US from February 2017 with pre-sales starting end of January. The wearable device was designed to combine activity tracking, skin temperature monitoring and body position detection, with data sent wirelessly in real time or stored on the device for subsequent analysis. It can be worn on any part of the body for a long duration and is ideal for a number of general healthcare applications. These include the monitoring of chronic diseases and sleep disorders as well as for monitoring overweight people included in adapted physical activity-based rehabilitation programs.
The Blood Pulse Wave device is a piezoelectric flexible sensor based on BodyCap’s patented Upper Skin technology. It can detect the blood pulse wave and its changes while exposed to long-term microgravity. It has been developed in partnership with the Paris-based engineering school ESIEE.
“Devices used in space for scientific missions have to meet the strict criteria of rigorous quality checks by space agencies. We are delighted that in the new year we can bring e-Tact technology to everyday e-health applications,” said Sébastien Moussay, co-founder of BodyCap and associate professor in the INSERM Lab COMETE U1075. “The successful use of monitoring devices on the ISS proves the reliability and accuracy of our products. We are now actively looking for investors to support us with the international roll-out of the product.”
According to IDTechEx, the global wearable technology market will grow in three stages: 9% annually to over $40 billion (€37.7bn) in 2018, then accelerating to 23% - over $100 billion (€94.2bn) - by 2023, before slowing to 10% to reach over $150 billion (€141.3bn) by 2026. The market for wearables for activity tracking and e-health applications has a huge potential and is in crucial need of reliable technologies.
BodyCap has extensive experience in the development of connected miniaturized devices. One of its already marketed devices is the e-Celsius Performance® connected pill. This has been used for internal temperature monitoring during major world sports events, including the Olympics and the New York Marathon as well as international cycling events, besides being used by the military.
BodyCap will be attending CES 2017 in Las Vegas, January 5 - 8 - meet us there.
BodyCap develops miniature wireless electronic sensors and embedded monitoring solutions for health monitoring. Specializing in wearable connected devices for physiological data surveillance, its innovative high-tech products are used in sports performance enhancement, medical research and development and to monitor people in extreme environments.
Having received medical device certifications ISO13485 and ISO9001, BodyCap is able to design products that meet current standards and regulations. Its scientific board is made up of professors of medicine and pharmacology. BodyCap works in partnership with global technological companies (TOTEMSPARK), research laboratories (INSERM) and engineering schools (ESIEE).
BodyCap was founded in 2011 by Fabrice Verjus, doctor of electronics, and Sébastien Moussay, doctor of sports science. The company is based in Caen, France and has 15 employees. It has an exclusive license for use of a Philips patent and owns two other patents. Between 2013 and 2015, BodyCap raised €1M ($1.1M) from a French investment fund, GO Capital.
// end //